Form 8-K - Current report:
SEC Accession No. 0001558370-25-002541
Filing Date
2025-03-10
Accepted
2025-03-10 08:30:26
Documents
17
Period of Report
2025-03-09
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fbio-20250309x8k.htm   iXBRL 8-K 88485
2 EX-2.1 fbio-20250309xex2d1.htm EX-2.1 1154534
3 EX-10.1 fbio-20250309xex10d1.htm EX-10.1 150480
4 EX-10.2 fbio-20250309xex10d2.htm EX-10.2 157477
  Complete submission text file 0001558370-25-002541.txt   2006715

Data Files

Seq Description Document Type Size
5 EX-101.SCH fbio-20250309.xsd EX-101.SCH 4557
6 EX-101.DEF fbio-20250309_def.xml EX-101.DEF 14892
7 EX-101.LAB fbio-20250309_lab.xml EX-101.LAB 17167
8 EX-101.PRE fbio-20250309_pre.xml EX-101.PRE 14857
19 EXTRACTED XBRL INSTANCE DOCUMENT fbio-20250309x8k_htm.xml XML 7160
Mailing Address 1111 KANE CONCOURSE SUITE 301 BAY HARBOR ISLANDS FL 33154
Business Address 1111 KANE CONCOURSE SUITE 301 BAY HARBOR ISLANDS FL 33154 781-652-4500
Fortress Biotech, Inc. (Filer) CIK: 0001429260 (see all company filings)

EIN.: 205157386 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35366 | Film No.: 25722277
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)